CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells

Wang,Zhenxing; Li,Lanxin; Chu,Chunhong; Wei,Xiangkai; Liu,Qian; Wang,Rui; Zhang,Guoliang; Wu,Guangyao; Wang,Ying; An,Lei; Li,Xiaodong

doi:10.3892/ijo.2023.5579

CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells

Authors:
- Zhenxing Wang
- Lanxin Li
- Chunhong Chu
- Xiangkai Wei
- Qian Liu
- Rui Wang
- Guoliang Zhang
- Guangyao Wu
- Ying Wang
- Lei An
- Xiaodong Li
View Affiliations

Affiliations: Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan 475000, P.R. China, School of Pharmacy, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, Henan 475000, P.R. China, Department of Anesthesiology, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, Henan 475000, P.R. China
Published online on: October 12, 2023 https://doi.org/10.3892/ijo.2023.5579
Article Number: 131
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer is one of the most common urological malignancies worldwide. The molecular mechanism underlying its development is complex, but its carcinogenesis has been proposed to occur with cell proliferation and resistance to apoptosis, driven by the signaling activity of abundant EGFR and receptor tyrosine‑protein kinase erbB‑2. In the present study, T24 bladder cancer cell lines with EGFR‑overexpression were constructed, before the multi‑target inhibitor CUDC‑101 was used to investigate its potential as a targeted therapeutic agent for bladder cancer using chemosensitivity methods. The results showed that CUDC‑101 induced cytotoxic effects, inhibited growth vitality and proliferation in a dose‑dependent manner. CUDC‑101 also altered the skeletal morphology and microfilament structure, while blocking cell cycle progression and causing apoptosis. These results supported the proposed cytotoxic effects of CUDC‑101, in addition to its inhibitory effects on cell division and proliferation in EGFR‑overexpressing bladder cancer cells. Therefore CUDC‑101 may to be a potential therapeutic option for the treatment of bladder cancer.

View Figures

View References

1	Dobruch J and Oszczudlowski M: Bladder cancer: Current challenges and future directions. Medicina (Kaunas). 57:7492021. View Article : Google Scholar : PubMed/NCBI
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Kim IH and Lee HJ: Perioperative systemic treatment for muscle-invasive bladder cancer: Current evidence and future perspectives. Int J Mol Sci. 22:72012021. View Article : Google Scholar : PubMed/NCBI
4	Lenis AT, Lec PM, Chamie K and Mshs MD: Bladder cancer: A review. JAMA. 324:1980–1991. 2020. View Article : Google Scholar : PubMed/NCBI
5	Guo CC and Czerniak B: Bladder cancer in the genomic era. Arch Pathol Lab Med. 143:695–704. 2019. View Article : Google Scholar : PubMed/NCBI
6	Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN and Ueno NT: Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 136:331–345. 2012. View Article : Google Scholar : PubMed/NCBI
7	O'Leary C, Gasper H, Sahin KB, Tang M, Kulasinghe A, Adams MN, Richard DJ and O'Byrne KJ: Epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). Pharmaceuticals (Basel). 13:2732020. View Article : Google Scholar : PubMed/NCBI
8	Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, et al: Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 23:603–617. 2013. View Article : Google Scholar : PubMed/NCBI
9	Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014. View Article : Google Scholar
10	Arteaga CL and Engelman JA: ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 25:282–303. 2014. View Article : Google Scholar : PubMed/NCBI
11	Sabbah DA, Hajjo R and Sweidan K: Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 20:815–834. 2020. View Article : Google Scholar : PubMed/NCBI
12	Sigismund S, Avanzato D and Lanzetti L: Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018. View Article : Google Scholar :
13	Wang Z: ErbB receptors and cancer. Methods Mol Biol. 1652:3–35. 2017. View Article : Google Scholar : PubMed/NCBI
14	Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, et al: CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 70:3647–3656. 2010. View Article : Google Scholar : PubMed/NCBI
15	Wang J, Pursell NW, Samson ME, Atoyan R, Ma AW, Selmi A, Xu W, Cai X, Voi M, Savagner P and Lai CJ: Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther. 12:925–936. 2013. View Article : Google Scholar : PubMed/NCBI
16	Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, Rasco DW, Mays TA, Chambers G, Ma A, et al: Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. Clin Cancer Res. 20:5032–5040. 2014. View Article : Google Scholar : PubMed/NCBI
17	Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R and Qian C: Discovery of 7-[4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy]-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 53:2000–2009. 2010. View Article : Google Scholar : PubMed/NCBI
18	Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, et al: A Phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 21:1566–1573. 2015. View Article : Google Scholar : PubMed/NCBI
19	Martinez Rodriguez RH, Buisan Rueda O and Ibarz L: Bladder cancer: Present and future. Med Clin (Barc). 149:449–455. 2017.In English, Spanish. View Article : Google Scholar : PubMed/NCBI
20	Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR and Boorjian SA: Gender and bladder cancer: A collaborative review of etiology, biology, and outcomes. Eur Urol. 69:300–310. 2016. View Article : Google Scholar
21	Pham A and Ballas LK: Trimodality therapy for bladder cancer: Modern management and future directions. Curr Opin Urol. 29:210–215. 2019. View Article : Google Scholar : PubMed/NCBI
22	Ahmadi H, Duddalwar V and Daneshmand S: Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am. 35:531–541. 2021. View Article : Google Scholar : PubMed/NCBI
23	Seidl C: Targets for therapy of bladder cancer. Semin Nucl Med. 50:162–170. 2020. View Article : Google Scholar : PubMed/NCBI
24	Tang Y, Zhang X, Qi F, Chen M, Li Y, Liu L, He W, Li Z and Zu X: Afatinib inhibits proliferation and invasion and promotes apoptosis of the T24 bladder cancer cell line. Exp Ther Med. 9:1851–1856. 2015. View Article : Google Scholar : PubMed/NCBI
25	Przybojewska B, Jagiello A and Jalmuzna P: H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Cancer Genet Cytogenet. 121:73–77. 2000. View Article : Google Scholar : PubMed/NCBI
26	Denny WA: The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. Farmaco. 56:51–56. 2001. View Article : Google Scholar : PubMed/NCBI
27	An L, Wang Y, Wu G, Wang Z, Shi Z, Liu C, Wang C, Yi M, Niu C, Duan S, et al: Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors. Transl Res. 255:14–25. 2023. View Article : Google Scholar
28	Sun H, Mediwala SN, Szafran AT, Mancini MA and Marcelli M: CUDC-101, a novel inhibitor of full-length androgen receptor (flAR) and androgen receptor variant 7 (AR-V7) activity: Mechanism of action and in vivo efficacy. Horm Cancer. 7:196–210. 2016. View Article : Google Scholar : PubMed/NCBI
29	Oliveira-Silva RJ, Carolina de Carvalho A, de Souza Viana L, Carvalho AL and Reis RM: Anti-EGFR therapy: Strategies in head and neck squamous cell carcinoma. Recent Pat Anticancer Drug Discov. 11:170–183. 2016. View Article : Google Scholar : PubMed/NCBI
30	Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, et al: Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget. 6:9073–9085. 2015. View Article : Google Scholar : PubMed/NCBI
31	Moertl S, Payer S, Kell R, Winkler K, Anastasov N and Atkinson MJ: Comparison of radiosensitization by HDAC inhibitors CUDC-101 and SAHA in pancreatic cancer cells. Int J Mol Sci. 20:35292019. View Article : Google Scholar
32	Bass AKA, El-Zoghbi MS, Nageeb EM, Mohamed MFA, Badr M and Abuo-Rahma GEA: Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur J Med Chem. 209:1129042021. View Article : Google Scholar
33	Pegoraro AF, Janmey P and Weitz DA: Mechanical properties of the cytoskeleton and cells. Cold Spring Harb Perspect Biol. 9:a0220382017. View Article : Google Scholar : PubMed/NCBI
34	Bottone MG, Santin G, Aredia F, Bernocchi G, Pellicciari C and Scovassi AI: Morphological features of organelles during apoptosis: An overview. Cells. 2:294–305. 2013. View Article : Google Scholar : PubMed/NCBI
35	Liu C, Wang Z, Liu Q, Wu G, Chu C, Li L, An L and Duan S: Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors. Clin Transl Oncol. 24:1975–1985. 2022. View Article : Google Scholar : PubMed/NCBI
36	Annesley SJ and Fisher PR: Mitochondria in health and disease. Cells. 8:6802019. View Article : Google Scholar : PubMed/NCBI
37	Sakamuru S, Attene-Ramos MS and Xia M: Mitochondrial membrane potential assay. Methods Mol Biol. 1473:17–22. 2016. View Article : Google Scholar : PubMed/NCBI
38	Hussain S: Measurement of nanoparticle-induced mitochondrial membrane potential alterations. Methods Mol Biol. 1894:123–131. 2019. View Article : Google Scholar
39	Chong CR and Jänne PA: The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 19:1389–1400. 2013. View Article : Google Scholar : PubMed/NCBI
40	Yue X, Li M, Chen D, Xu Z and Sun S: UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells. Exp Ther Med. 16:3921–3928. 2018.PubMed/NCBI
41	Yang Q, Modi P, Newcomb T, Quéva C and Gandhi V: Idelalisib: First-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 21:1537–1542. 2015. View Article : Google Scholar : PubMed/NCBI